“Like a pickle that’s been unpickled”: Emotional, identity and behavioural transformations throughout hepatitis C treatment

Background Little is known about the emotional experience and benefits of undertaking direct acting antiviral (DAA) treatment for hepatitis C. A better understanding of individual treatment outcomes can inform acceptable treatment delivery and promotion. We aimed to explore participant-perceived emotional benefits and transformations throughout DAA treatment among people who inject drugs, who were initiating treatment. Methods Participants were recruited from either a community based clinical trial or community health clinics. Semi structured interviews were conducted with each participant before, during and following treatment. Interviews focussed on treatment perceptions, physical and mental wellbeing and modifiable health behaviours. Interviews were recorded, transcribed verbatim and thematically analysed. Participant and cohort matrices were produced to assess at which time point themes were present and whether themes changed or remained stable over time. Results This paper presents analysis from 19 participants interviewed between 2017–2019. Most participants were male, with no or mild fibrosis. At baseline, all but one participant had injected drugs in the past month. Three themes relating to the emotional wellbeing and behaviour change described a common treatment experience; ‘hopes for better wellbeing’, ‘lifting the weight’ and ‘closing the chapter’. Participants were hopeful treatment would improve their emotional wellbeing. Hopes were actualised during treatment as participants began to feel uncertainty and stress easing. Completing treatment improved some participants perceptions of self. Some participants consciously changed their injecting behaviours during treatment. Conclusion Undertaking and completing treatment was an emotionally and behaviourally transformative period. Participant perceived benefits should be used to inform how treatment benefit is conceptualised and how treatment is promoted in primary care settings.

[1]  M. Hellard,et al.  Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study , 2021, Harm Reduction Journal.

[2]  M. Hellard,et al.  Patient‐reported outcomes of the Treatment and Prevention Study: A real‐world community‐based trial of direct‐acting antivirals for hepatitis C among people who inject drugs , 2021, Journal of viral hepatitis.

[3]  M. Hellard,et al.  Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study. , 2020, The International journal on drug policy.

[4]  G. Fitzgerald,et al.  ‘I’m over the moon!’: patient-perceived outcomes of hepatitis C treatment , 2020 .

[5]  P. Carrieri,et al.  Life after hepatitis C cure in HIV‐infected people who inject drugs and men who have sex with men treated with direct‐acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH) , 2020, Journal of Viral Hepatitis.

[6]  Narelle Warren,et al.  Post-cure , 2020, Medicine Anthropology Theory.

[7]  T. Rhodes,et al.  How to think with models and targets: Hepatitis C elimination as a numbering performance. , 2020, The International journal on drug policy.

[8]  M. Hellard,et al.  Australia needs to increase testing to achieve hepatitis C elimination , 2020, The Medical journal of Australia.

[9]  T. Rhodes,et al.  "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination. , 2020, The International journal on drug policy.

[10]  M. Hellard,et al.  Treatment access is only the first step to hepatitis C elimination: experience of universal anti‐viral treatment access in Australia , 2019, Alimentary pharmacology & therapeutics.

[11]  M. Hellard,et al.  FRI-228-Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention) study , 2019, Journal of Hepatology.

[12]  A. Gifford,et al.  Experiences with interferon-free hepatitis C therapies: addressing barriers to adherence and optimizing treatment outcomes , 2019, BMC Health Services Research.

[13]  M. Hellard,et al.  Improving hepatitis C direct‐acting antiviral access and uptake: A role for patient‐reported outcomes and lived experience , 2018, Journal of viral hepatitis.

[14]  C. Treloar,et al.  Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia , 2018, Harm Reduction Journal.

[15]  M. Hellard,et al.  Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia , 2018, Hepatology, Medicine and Policy.

[16]  L. Elliott,et al.  Hepatitis C in a new therapeutic era: Recontextualising the lived experience , 2018, Journal of clinical nursing.

[17]  M. Harris Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'. , 2017, The International journal on drug policy.

[18]  L. Elliott,et al.  The lived experience of interferon-free treatments for hepatitis C: A thematic analysis. , 2016, The International journal on drug policy.

[19]  D. Grossoehme,et al.  Analyzing longitudinal qualitative data: the application of trajectory and recurrent cross-sectional approaches , 2016, BMC Research Notes.

[20]  David A. Rolls,et al.  Hepatitis C transmission and treatment as prevention - The role of the injecting network. , 2015, The International journal on drug policy.

[21]  A. Gifford,et al.  Resolute efforts to cure hepatitis C: Understanding patients’ reasons for completing antiviral treatment , 2015, Health.

[22]  J. Arnsten,et al.  "Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment. , 2015, Drug and alcohol dependence.

[23]  M. Stepanova,et al.  The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon‐ and ribavirin‐free regimens: a study of health‐related quality of life , 2015, Alimentary pharmacology & therapeutics.

[24]  Z. Younossi,et al.  The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment , 2015, Therapeutic advances in gastroenterology.

[25]  L. Henry,et al.  Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens , 2015, Alimentary pharmacology & therapeutics.

[26]  M. Guha The Wiley-Blackwell Encyclopedia of Health, Illness, Behavior and Society , 2014 .

[27]  D. Semela,et al.  “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis , 2014, BMC Infectious Diseases.

[28]  M. Hellard,et al.  Eradication of hepatitis C infection: The importance of targeting people who inject drugs , 2013, Hepatology.

[29]  M. Kinder The Lived Experience of Treatment for Hepatitis C , 2009, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[30]  M. Harris Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis. , 2009, Sociology of health & illness.

[31]  Carla Treloar,et al.  The Lived Experience of Hepatitis C and its Treatment Among Injecting Drug Users: Qualitative Synthesis , 2009, Qualitative health research.

[32]  Patricia Taylor-Young,et al.  The Multidimensional Burden of Hepatitis C and Its Treatment: A Case Study , 2009, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[33]  C. Treloar,et al.  Resilient Coping , 2008, Journal of health psychology.

[34]  D. Vlahov,et al.  Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.

[35]  C. Treloar,et al.  Chronic Illness Experiences, Clinical Markers and Living with Hepatitis C , 2007, Journal of health psychology.

[36]  K. Sheppard,et al.  The Patient Experience of Treatment for Hepatitis C , 2006, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[37]  D. Battistutta,et al.  Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. , 2006, Journal of pain and symptom management.

[38]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[39]  C. Treloar,et al.  The Experience of Interferon-Based Treatments for Hepatitis C Infection , 2005, Qualitative health research.

[40]  R. Hays,et al.  Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment , 2005, Hepatology.

[41]  Belinda Crockett,et al.  “Eyes Wide Shut”: Narratives of Women Living with Hepatitis C in Australia , 2004, Women & health.

[42]  David Calvey Longitudinal Qualitative Research: Analyzing Change Through Time , 2004 .

[43]  Johnny Saldaña,et al.  Longitudinal Qualitative Research: Analyzing Change Through Time , 2003 .

[44]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[45]  V. Coates,et al.  Diagnosed with Hepatitis C: a descriptive exploratory study. , 2001, International journal of nursing studies.

[46]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[47]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[48]  C. Dolea,et al.  World Health Organization , 1949, International Organization.